Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation

Fig. 3

The MIC distribution of TGC in monotherapy or combination with FOS against 136 KPC-producing Klebsiella. pneumoniae, and probability of target attainment (PTA) of 6.93 AUC24/MIC for TGC dosing regimens in critically ill elderly patients with normal renal function (Left) and renal impairment (right). The dotted line indicates the PTA of 0.9. FOS, fosfomycin; TGC, tigecycline

Back to article page
\